Faster, cheaper, more accurate pain diagnosis.

Lutroo:

λυτρόω (Greek)

To release, to be set free.

Lutroo Imaging is creating the world’s first technology to visually pinpoint the source of pain and objectively measure its intensity.  This will greatly improve diagnosis and allow targeted therapy sooner, and set patients free from pain.

Above: The first ever image of pain, showing a stronger signal in the painful nerve compared to a healthy nerve using Radiocaine PET imaging.

What we do

Lutroo Imaging is able to show pain visually through the use of PET scanners, specialized equipment commonly used by healthcare professionals around the world. PET, or Positron Emission Tomography, is similar to MRI as a non-invasive imaging technology that delivers 3D images of the body. Different to MRI, which takes pictures of structure, a PET scan uses ‘radiotracers’ that visualize and measure changes in function. A radiotracer is injected into a patient and subsequently detected by the PET scanner. Lutroo Imaging is developing Radiocaine, a specialized ‘radiotracer’ that selectively labels pain-transmitting nerves, which illuminate on the PET scan, thereby revealing the source of pain.

Pain is difficult to diagnose and treat effectively:

1 in 5

adults suffer from chronic pain worldwide

>$600B

annual economic burden in the USA alone

15

average healthcare visits before proper diagnosis

85%

of pain sufferers never achieve pain freedom

What is Radiocaine?

Radiocaine, also known as 18F-Fluorolidocaine, is a modified compound of a local anesthetic which has been FDA-approved since 1948. By attaching an 18F-isotope, Radiocaine can be used as a PET radiotracer that labels pain-transmitting nerves by highlighting ‘voltage-gated sodium channels’ (NaVs) in a patient. In chronic pain sufferers, nerves have too many NaVs, which causes excessive pain signaling. Healthcare professionals are now able to see exactly which nerves have excessive NaVs, and treat patients accordingly.